Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial

J. Sanyal, Arun; López, Patricia; Lawitz, Eric; Jean Lucas, Kathryn; Loeffler, Juergen; Kim, Won; Boon‐Bee Goh, George; Huang, Jee‐Fu; Serra, Carla; Andreoné, Pietro; Chen, Yi‐Cheng; H. Hsia, Stanley; Ratziu, Vlad; Aizenberg, Diego; Tobita, Hiroshi; Sheikh, Aasim; M. Vierling, John; Jun Kim, Yoon; Hyogo, Hideyuki; Tai, Dean; Goodman, Zachary; Schaefer, F; R. I. Carbarns, Ian; Lamle, Sophie; Martić, Miljen; V. Naoumov, Nikolai; A. Brass, Clifford

doi:10.1038/s41591-022-02200-8

Public

Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial

Published in Nature Medicine • Feb 1, 2023

Authors:

Arun J. Sanyal

Patricia López

Eric Lawitz

Abstract

Abstract The multimodal activities of farnesoid X receptor (FXR) agonists make this class an attractive option to treat nonalcoholic steatohepatitis. The safety and efficacy of tropifexor, an FXR agonist, in a randomized, multicenter, double-blind, three-part adaptive design, phase 2 study, in patie...

Subject

Placebo

Tolerability

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!